Frank Scott
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 28 | 2026 | 365 | 8.350 |
Why?
| | Crohn Disease | 16 | 2025 | 260 | 5.470 |
Why?
| | Gastrointestinal Agents | 7 | 2025 | 66 | 3.330 |
Why?
| | Gastroenterology | 7 | 2025 | 188 | 2.090 |
Why?
| | Colitis, Ulcerative | 9 | 2025 | 147 | 2.050 |
Why?
| | Infliximab | 10 | 2022 | 108 | 1.520 |
Why?
| | Intestinal Obstruction | 3 | 2021 | 56 | 1.440 |
Why?
| | Immunosuppressive Agents | 6 | 2020 | 846 | 1.240 |
Why?
| | Tissue Adhesions | 3 | 2021 | 34 | 1.230 |
Why?
| | Adrenal Cortex Hormones | 4 | 2022 | 478 | 1.120 |
Why?
| | Tumor Necrosis Factor-alpha | 10 | 2023 | 1217 | 1.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2025 | 985 | 1.050 |
Why?
| | Algorithms | 7 | 2026 | 1834 | 0.990 |
Why?
| | Intestine, Small | 2 | 2021 | 166 | 0.940 |
Why?
| | Patient Acceptance of Health Care | 5 | 2026 | 878 | 0.930 |
Why?
| | Biological Products | 4 | 2026 | 251 | 0.910 |
Why?
| | Ustekinumab | 2 | 2025 | 17 | 0.880 |
Why?
| | JC Virus | 2 | 2015 | 23 | 0.860 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2015 | 38 | 0.850 |
Why?
| | Azathioprine | 5 | 2021 | 49 | 0.790 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 56 | 0.780 |
Why?
| | Humans | 91 | 2026 | 144261 | 0.770 |
Why?
| | Abdominal Abscess | 1 | 2022 | 25 | 0.730 |
Why?
| | Abdomen | 2 | 2021 | 141 | 0.730 |
Why?
| | Drug Monitoring | 1 | 2026 | 389 | 0.730 |
Why?
| | Esophageal Neoplasms | 6 | 2022 | 346 | 0.720 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2023 | 136 | 0.670 |
Why?
| | Postoperative Complications | 3 | 2021 | 2916 | 0.660 |
Why?
| | Severity of Illness Index | 9 | 2025 | 2917 | 0.650 |
Why?
| | Splints | 1 | 2020 | 14 | 0.650 |
Why?
| | Retrospective Studies | 27 | 2026 | 17009 | 0.650 |
Why?
| | Capsule Endoscopy | 1 | 2020 | 25 | 0.640 |
Why?
| | Anti-Bacterial Agents | 5 | 2018 | 1906 | 0.640 |
Why?
| | Antibodies, Viral | 2 | 2015 | 672 | 0.630 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 28 | 0.620 |
Why?
| | Barrett Esophagus | 4 | 2023 | 165 | 0.600 |
Why?
| | Biomedical Research | 2 | 2019 | 709 | 0.600 |
Why?
| | Radius Fractures | 1 | 2020 | 69 | 0.600 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 434 | 0.590 |
Why?
| | Quality-Adjusted Life Years | 5 | 2021 | 117 | 0.580 |
Why?
| | Spondylarthritis | 3 | 2025 | 50 | 0.580 |
Why?
| | Colonoscopy | 7 | 2024 | 260 | 0.560 |
Why?
| | Drug Utilization | 1 | 2019 | 166 | 0.550 |
Why?
| | Intestinal Fistula | 1 | 2018 | 17 | 0.550 |
Why?
| | Adult | 37 | 2026 | 40262 | 0.550 |
Why?
| | Colonic Diseases | 1 | 2018 | 34 | 0.540 |
Why?
| | Hospitalization | 4 | 2026 | 2424 | 0.540 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 268 | 0.540 |
Why?
| | Health Resources | 1 | 2019 | 129 | 0.540 |
Why?
| | Tuberculin Test | 1 | 2017 | 36 | 0.540 |
Why?
| | Pericardium | 1 | 2018 | 62 | 0.530 |
Why?
| | Cost-Benefit Analysis | 5 | 2021 | 623 | 0.530 |
Why?
| | Biological Factors | 2 | 2023 | 39 | 0.520 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 101 | 0.520 |
Why?
| | Models, Statistical | 2 | 2019 | 677 | 0.510 |
Why?
| | Latent Tuberculosis | 1 | 2017 | 71 | 0.500 |
Why?
| | Male | 48 | 2026 | 72035 | 0.490 |
Why?
| | Mass Screening | 4 | 2021 | 1332 | 0.490 |
Why?
| | Middle Aged | 37 | 2026 | 35762 | 0.490 |
Why?
| | Time-to-Treatment | 2 | 2019 | 240 | 0.490 |
Why?
| | Colorectal Neoplasms | 6 | 2024 | 844 | 0.480 |
Why?
| | Remission Induction | 3 | 2025 | 306 | 0.470 |
Why?
| | Treatment Outcome | 14 | 2025 | 11643 | 0.460 |
Why?
| | Antibodies, Monoclonal | 4 | 2021 | 1519 | 0.460 |
Why?
| | Natalizumab | 1 | 2015 | 41 | 0.450 |
Why?
| | Radius | 1 | 2015 | 52 | 0.450 |
Why?
| | Heart Diseases | 1 | 2018 | 349 | 0.430 |
Why?
| | Fracture Fixation | 1 | 2015 | 79 | 0.430 |
Why?
| | Models, Theoretical | 1 | 2018 | 582 | 0.420 |
Why?
| | Mycobacterium tuberculosis | 1 | 2017 | 334 | 0.410 |
Why?
| | Age Factors | 5 | 2025 | 3313 | 0.410 |
Why?
| | Female | 44 | 2026 | 77976 | 0.400 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1347 | 0.400 |
Why?
| | Leukocyte L1 Antigen Complex | 2 | 2026 | 40 | 0.390 |
Why?
| | Aged | 27 | 2024 | 25850 | 0.390 |
Why?
| | Markov Chains | 3 | 2020 | 126 | 0.380 |
Why?
| | Lymphoma | 1 | 2014 | 232 | 0.380 |
Why?
| | Risk Factors | 17 | 2025 | 10699 | 0.370 |
Why?
| | Drug Therapy, Combination | 4 | 2024 | 1044 | 0.370 |
Why?
| | Adalimumab | 3 | 2021 | 55 | 0.360 |
Why?
| | Communicable Diseases | 1 | 2014 | 163 | 0.360 |
Why?
| | Patient Discharge | 2 | 2023 | 977 | 0.350 |
Why?
| | United Kingdom | 5 | 2021 | 336 | 0.350 |
Why?
| | Feces | 3 | 2026 | 513 | 0.340 |
Why?
| | Gastroenterologists | 2 | 2022 | 21 | 0.340 |
Why?
| | Professional Competence | 1 | 2012 | 98 | 0.340 |
Why?
| | Disease Management | 3 | 2021 | 643 | 0.340 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 641 | 0.330 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 338 | 0.320 |
Why?
| | Cohort Studies | 10 | 2025 | 5935 | 0.320 |
Why?
| | Research Design | 2 | 2019 | 1129 | 0.320 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 43 | 0.320 |
Why?
| | Gastroesophageal Reflux | 2 | 2023 | 236 | 0.320 |
Why?
| | Research Personnel | 1 | 2012 | 183 | 0.310 |
Why?
| | Adenoma | 3 | 2024 | 218 | 0.310 |
Why?
| | Fractures, Bone | 1 | 2015 | 414 | 0.310 |
Why?
| | Colonic Polyps | 2 | 2024 | 85 | 0.310 |
Why?
| | United States | 17 | 2025 | 15876 | 0.300 |
Why?
| | Proportional Hazards Models | 5 | 2021 | 1322 | 0.290 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2017 | 255 | 0.290 |
Why?
| | Pediatric Obesity | 1 | 2016 | 624 | 0.280 |
Why?
| | Janus Kinase Inhibitors | 2 | 2025 | 28 | 0.280 |
Why?
| | Skin Neoplasms | 1 | 2016 | 847 | 0.280 |
Why?
| | Societies, Medical | 4 | 2025 | 886 | 0.280 |
Why?
| | Incidence | 8 | 2021 | 2870 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1705 | 0.260 |
Why?
| | Quality of Life | 2 | 2021 | 3166 | 0.260 |
Why?
| | Electronic Health Records | 6 | 2022 | 1169 | 0.260 |
Why?
| | Consensus | 2 | 2025 | 488 | 0.240 |
Why?
| | Mortality | 2 | 2020 | 371 | 0.240 |
Why?
| | Databases, Factual | 7 | 2018 | 1484 | 0.240 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 1137 | 0.230 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 42 | 0.230 |
Why?
| | Radiography | 2 | 2020 | 842 | 0.230 |
Why?
| | Population Surveillance | 2 | 2021 | 483 | 0.230 |
Why?
| | Adenocarcinoma | 3 | 2022 | 927 | 0.230 |
Why?
| | Induction Chemotherapy | 1 | 2025 | 87 | 0.220 |
Why?
| | Referral and Consultation | 2 | 2023 | 847 | 0.220 |
Why?
| | Antifungal Agents | 2 | 2016 | 149 | 0.220 |
Why?
| | Evidence-Based Medicine | 2 | 2025 | 729 | 0.220 |
Why?
| | Aged, 80 and over | 10 | 2020 | 8243 | 0.210 |
Why?
| | Case-Control Studies | 8 | 2021 | 3592 | 0.210 |
Why?
| | Delivery of Health Care | 2 | 2021 | 940 | 0.210 |
Why?
| | Recurrence | 5 | 2021 | 1134 | 0.210 |
Why?
| | Esophageal Stenosis | 2 | 2014 | 57 | 0.210 |
Why?
| | Surveys and Questionnaires | 8 | 2025 | 6021 | 0.200 |
Why?
| | C-Reactive Protein | 1 | 2026 | 416 | 0.200 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 91 | 0.200 |
Why?
| | Obesity | 1 | 2017 | 3057 | 0.200 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 771 | 0.200 |
Why?
| | Esophagitis, Peptic | 1 | 2023 | 16 | 0.190 |
Why?
| | Protective Factors | 2 | 2021 | 99 | 0.190 |
Why?
| | Colectomy | 2 | 2021 | 107 | 0.190 |
Why?
| | Models, Economic | 2 | 2020 | 62 | 0.190 |
Why?
| | Logistic Models | 6 | 2018 | 2104 | 0.190 |
Why?
| | Glucocorticoids | 2 | 2018 | 533 | 0.190 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 275 | 0.190 |
Why?
| | Comparative Effectiveness Research | 2 | 2024 | 169 | 0.180 |
Why?
| | Cellulitis | 1 | 2022 | 53 | 0.180 |
Why?
| | Medical Marijuana | 1 | 2024 | 123 | 0.180 |
Why?
| | Prognosis | 4 | 2019 | 4278 | 0.180 |
Why?
| | Odds Ratio | 4 | 2018 | 1072 | 0.180 |
Why?
| | Insurance, Health | 1 | 2024 | 301 | 0.170 |
Why?
| | Necrosis | 1 | 2022 | 244 | 0.170 |
Why?
| | Amputation, Traumatic | 1 | 2021 | 21 | 0.170 |
Why?
| | Finger Injuries | 1 | 2021 | 26 | 0.170 |
Why?
| | Liver Transplantation | 2 | 2021 | 822 | 0.170 |
Why?
| | Rectal Fistula | 1 | 2021 | 27 | 0.170 |
Why?
| | Aftercare | 1 | 2023 | 220 | 0.170 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 918 | 0.160 |
Why?
| | Vascular Surgical Procedures | 2 | 2021 | 339 | 0.160 |
Why?
| | Prevalence | 4 | 2025 | 2815 | 0.160 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 64 | 0.160 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5389 | 0.160 |
Why?
| | Cystectomy | 2 | 2017 | 41 | 0.160 |
Why?
| | Utilization Review | 1 | 2020 | 39 | 0.160 |
Why?
| | Esophagoscopy | 2 | 2022 | 221 | 0.160 |
Why?
| | Sugars | 1 | 2020 | 41 | 0.160 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 109 | 0.160 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1559 | 0.160 |
Why?
| | Carcinoma | 1 | 2021 | 227 | 0.150 |
Why?
| | Bone Density | 1 | 2023 | 482 | 0.150 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 40 | 0.150 |
Why?
| | Bone Plates | 1 | 2020 | 80 | 0.150 |
Why?
| | Urologic Surgical Procedures | 1 | 2021 | 115 | 0.150 |
Why?
| | Tryptophan | 1 | 2021 | 180 | 0.150 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 336 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2024 | 365 | 0.150 |
Why?
| | Diabetes Mellitus | 2 | 2021 | 1092 | 0.150 |
Why?
| | Metagenomics | 1 | 2021 | 181 | 0.150 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1983 | 0.150 |
Why?
| | Hospitals | 2 | 2021 | 727 | 0.150 |
Why?
| | Deglutition Disorders | 1 | 2021 | 147 | 0.150 |
Why?
| | Hospitals, Veterans | 1 | 2020 | 259 | 0.150 |
Why?
| | Obesity, Morbid | 1 | 2023 | 275 | 0.150 |
Why?
| | Chronic Disease | 2 | 2022 | 1812 | 0.140 |
Why?
| | Child | 6 | 2023 | 22537 | 0.140 |
Why?
| | Metabolomics | 2 | 2022 | 726 | 0.140 |
Why?
| | Diverticulum | 1 | 2018 | 14 | 0.140 |
Why?
| | Job Satisfaction | 1 | 2021 | 240 | 0.140 |
Why?
| | Hematemesis | 1 | 2018 | 4 | 0.140 |
Why?
| | Health Care Costs | 1 | 2021 | 421 | 0.140 |
Why?
| | Symptom Assessment | 2 | 2017 | 137 | 0.140 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 421 | 0.140 |
Why?
| | Fracture Fixation, Internal | 1 | 2020 | 207 | 0.130 |
Why?
| | Infant | 5 | 2020 | 10022 | 0.130 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 291 | 0.130 |
Why?
| | Intestines | 1 | 2021 | 358 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2018 | 74 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2018 | 307 | 0.130 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2017 | 38 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 2 | 2016 | 1168 | 0.130 |
Why?
| | Ambulatory Care | 1 | 2021 | 597 | 0.130 |
Why?
| | Risk Assessment | 3 | 2016 | 3637 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2021 | 688 | 0.120 |
Why?
| | Cystadenoma, Mucinous | 1 | 2016 | 11 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 287 | 0.120 |
Why?
| | Budesonide | 1 | 2016 | 49 | 0.120 |
Why?
| | Itraconazole | 1 | 2016 | 7 | 0.120 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2016 | 61 | 0.120 |
Why?
| | Pharmacoepidemiology | 1 | 2015 | 22 | 0.120 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2023 | 237 | 0.120 |
Why?
| | Pancreatic Diseases | 1 | 2016 | 66 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2020 | 586 | 0.110 |
Why?
| | Cysts | 1 | 2016 | 111 | 0.110 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 100 | 0.110 |
Why?
| | Hyperlipidemias | 1 | 2016 | 121 | 0.110 |
Why?
| | Epiphyses | 1 | 2015 | 25 | 0.110 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1131 | 0.110 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5813 | 0.110 |
Why?
| | Data Accuracy | 1 | 2015 | 65 | 0.110 |
Why?
| | Antirheumatic Agents | 1 | 2018 | 303 | 0.110 |
Why?
| | Child, Preschool | 5 | 2016 | 11774 | 0.110 |
Why?
| | Arthritis, Juvenile | 1 | 2015 | 56 | 0.110 |
Why?
| | Polypharmacy | 1 | 2015 | 92 | 0.110 |
Why?
| | Psoriasis | 1 | 2016 | 112 | 0.110 |
Why?
| | Elbow Joint | 1 | 2015 | 74 | 0.110 |
Why?
| | Adolescent | 7 | 2019 | 22281 | 0.110 |
Why?
| | Hedgehog Proteins | 1 | 2016 | 197 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2015 | 110 | 0.100 |
Why?
| | Interferon-gamma | 1 | 2017 | 784 | 0.100 |
Why?
| | Neoplasms | 2 | 2023 | 2870 | 0.100 |
Why?
| | Cholesterol | 1 | 2016 | 399 | 0.100 |
Why?
| | Dilatation | 1 | 2014 | 72 | 0.100 |
Why?
| | Microbiota | 1 | 2022 | 781 | 0.100 |
Why?
| | Young Adult | 7 | 2019 | 13990 | 0.100 |
Why?
| | Burnout, Professional | 1 | 2021 | 484 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2016 | 255 | 0.100 |
Why?
| | Anastomosis, Surgical | 1 | 2014 | 157 | 0.100 |
Why?
| | Virus Diseases | 1 | 2016 | 216 | 0.100 |
Why?
| | Streptococcal Infections | 1 | 2016 | 168 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2014 | 151 | 0.100 |
Why?
| | Foreign Bodies | 1 | 2014 | 107 | 0.100 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 653 | 0.100 |
Why?
| | Disease Progression | 2 | 2021 | 2840 | 0.090 |
Why?
| | Early Detection of Cancer | 3 | 2022 | 462 | 0.090 |
Why?
| | Primary Health Care | 2 | 2022 | 1710 | 0.090 |
Why?
| | Reoperation | 1 | 2015 | 629 | 0.090 |
Why?
| | Diabetes Complications | 1 | 2013 | 220 | 0.090 |
Why?
| | Epidemiology | 1 | 2012 | 33 | 0.090 |
Why?
| | Registries | 1 | 2021 | 2382 | 0.090 |
Why?
| | Physical Therapy Modalities | 1 | 2015 | 332 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 79 | 0.090 |
Why?
| | Patient Readmission | 1 | 2017 | 756 | 0.090 |
Why?
| | Endoscopy | 1 | 2014 | 315 | 0.090 |
Why?
| | Tissue and Organ Procurement | 1 | 2015 | 346 | 0.090 |
Why?
| | Age Distribution | 1 | 2012 | 397 | 0.090 |
Why?
| | Biomarkers | 2 | 2020 | 4254 | 0.080 |
Why?
| | Time Factors | 5 | 2021 | 7155 | 0.080 |
Why?
| | Physicians | 1 | 2019 | 938 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2111 | 0.080 |
Why?
| | Veterans | 1 | 2021 | 1600 | 0.070 |
Why?
| | Prospective Studies | 4 | 2024 | 7970 | 0.070 |
Why?
| | Medicare | 3 | 2021 | 881 | 0.070 |
Why?
| | Drug Prescriptions | 2 | 2024 | 280 | 0.070 |
Why?
| | Laparoscopy | 1 | 2012 | 475 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2022 | 1461 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2301 | 0.060 |
Why?
| | Academic Medical Centers | 2 | 2021 | 545 | 0.060 |
Why?
| | Pennsylvania | 2 | 2017 | 136 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 964 | 0.060 |
Why?
| | Sex Factors | 2 | 2025 | 2096 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1382 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2447 | 0.050 |
Why?
| | Regression Analysis | 2 | 2017 | 998 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1533 | 0.050 |
Why?
| | Piperidines | 1 | 2024 | 217 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2024 | 238 | 0.050 |
Why?
| | Replantation | 1 | 2021 | 32 | 0.040 |
Why?
| | Cost Savings | 1 | 2021 | 86 | 0.040 |
Why?
| | Review Literature as Topic | 1 | 2021 | 53 | 0.040 |
Why?
| | Gastrectomy | 1 | 2023 | 157 | 0.040 |
Why?
| | Granzymes | 1 | 2021 | 49 | 0.040 |
Why?
| | Training Support | 1 | 2021 | 35 | 0.040 |
Why?
| | Documentation | 1 | 2023 | 197 | 0.040 |
Why?
| | Fingers | 1 | 2021 | 107 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 60 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 323 | 0.040 |
Why?
| | Hand | 1 | 2021 | 161 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 187 | 0.040 |
Why?
| | Perception | 1 | 2022 | 377 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 224 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 187 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3403 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 346 | 0.040 |
Why?
| | Physician's Role | 1 | 2021 | 218 | 0.040 |
Why?
| | Medicine | 1 | 2021 | 125 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 536 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 327 | 0.040 |
Why?
| | Career Choice | 1 | 2021 | 236 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2018 | 23 | 0.040 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 94 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 36 | 0.030 |
Why?
| | Smoking | 1 | 2025 | 1468 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 51 | 0.030 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 265 | 0.030 |
Why?
| | Hip Fractures | 1 | 2018 | 84 | 0.030 |
Why?
| | Mercaptopurine | 1 | 2016 | 15 | 0.030 |
Why?
| | Prednisone | 1 | 2018 | 221 | 0.030 |
Why?
| | Etanercept | 1 | 2016 | 60 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2926 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1867 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2088 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 680 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 59 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1241 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 758 | 0.030 |
Why?
| | Streptococcus pyogenes | 1 | 2016 | 41 | 0.030 |
Why?
| | Decision Making | 1 | 2023 | 974 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 464 | 0.030 |
Why?
| | Methotrexate | 1 | 2016 | 240 | 0.030 |
Why?
| | Bias | 1 | 2016 | 201 | 0.030 |
Why?
| | Weight Loss | 1 | 2021 | 832 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 676 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 427 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 508 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1782 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 1025 | 0.030 |
Why?
| | Mental Recall | 1 | 2015 | 222 | 0.020 |
Why?
| | Waiting Lists | 1 | 2015 | 263 | 0.020 |
Why?
| | Medicaid | 1 | 2018 | 461 | 0.020 |
Why?
| | Anticoagulants | 1 | 2018 | 721 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1982 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 396 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2134 | 0.010 |
Why?
|
|
Scott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|